European Commission Approves Roche’s Tecentriq-Avastin Combo Therapy

March 14, 2019

The European Commission has approved Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy for treating metastatic non-squamous non-small cell lung cancer (NSCLC).

The approval applies to first-line treatment of adult patients with metastatic NSCLC. For patients with EGFR mutant or ALK-positive NSCLC, the combo therapy is only indicated if appropriate targeted therapies have failed.

The commission’s green light was based on data from Roche’s Phase 3 study, which showed the combo therapy helped patients live significantly longer when compared with just Avastin and chemotherapy, the company said.

The FDA approved the Tecentriq-Avastin combo for treating NSCLC in December 2018. The agency had already cleared Tecentriq for treating metastatic NSCLC patients who have disease progression during or after platinum chemotherapy.

View today's stories